# GV1001 Subcutaneous(SC) for the Treatment of Moderate Alzheimer's Disease (AD)

> **NCT03959553** · PHASE2 · WITHDRAWN · sponsor: **GemVax & Kael**

## Conditions studied

- Moderate Alzheimer's Disease

## Interventions

- **DRUG:** GV1001
- **DRUG:** Normal saline

## Key facts

- **NCT ID:** NCT03959553
- **Lead sponsor:** GemVax & Kael
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-09-01
- **Primary completion:** 2021-08-31
- **Final completion:** 2022-02-28
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The study was stopped due to protocol amendment and project name change.
- **Last updated:** 2022-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03959553

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03959553, "GV1001 Subcutaneous(SC) for the Treatment of Moderate Alzheimer's Disease (AD)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03959553. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*